siRNA silencing of the MAPK pathway genes by targeting either the raf-1, mekk1, or mlk3 in acute myeloid leukemia (AML) cells was found to knockdown expression levels of between 40% and 60%. The gene discussed is RAF1; the disease is acute myeloid leukemia.